News
Preliminary results for the year ended 31 December 2025
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue growth of 33% to £170.9 million (CC) (FY 2024: £128.8……
View details >OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms
Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into……
View details >OXB announces date for Capital Markets Day and participation in upcoming investor conferences
Oxford, UK – 3 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces the date of its Capital Markets Day and participation at upcoming investor conferences. Capital Markets Day OXB will hold……
View details >Full year Trading Update and Notice of Results
Revenues at the upper end of guidance and pivot to EBITDA profitability – expectations for 2026 unchanged and guidance reiterated Revenues expected to increase c.30% as OXB continues to execute its strategy, FY 2025 revenues expected to be £166-169……
View details >OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell……
View details >OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards……
View details >OXB to participate in upcoming investor conferences and events
Oxford, UK – 27 October 2025:OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that members of its senior management team, including Dr. Frank Mathias, Chief Executive Officer, and Dr. Lucy Crabtree, Chief Financial……
View details >OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across drug substance and fill-finish to meet growing client demand Strengthens OXB’s global CDMO……
View details >Oxford Biomedica PLC Interim results for the six months ended 30 June 2025
Strong H1 2025 financial results, confirming confidence in the near and medium-term outlook Total revenues in H1 2025 increased by 44% to £73.2 million (£73.4 million constant currency) (H1 2024: £50.8 million), demonstrating continued momentum £149 million contracted value of……
View details >
